Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 10/20 | 0.73 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24032787 | 0.86 | LTA4H (0.75) | LTA4HSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3503717 | 0.86 | LTA4H (0.75) | LTA4HSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3503714 | 0.86 | LTA4H (0.75) | LTA4HSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL29398310 | 0.86 | LTA4H (0.75) | LTA4HSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3192017 | 0.86 | LTA4H (0.75) | LTA4HSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL2522620 | 0.85 | LTA4H (0.91) | LTA4HSLC1A3SLC1A2SLC1A1MAPT | |
| SCHEMBL176813 | 0.85 | LTA4H (0.91) | LTA4HSLC1A3SLC1A2SLC1A1MAPT | |
| SCHEMBL26153209 | 0.85 | GAA (0.57) | LTA4HSLC1A3SLC1A2SLC1A1MAPT | |
| SCHEMBL30442012 | 0.85 | GAA (0.57) | LTA4HSLC1A3SLC1A2SLC1A1MAPT | |
| SCHEMBL11336055 | 0.84 | LTA4H (0.73) | LTA4HSLC1A3SLC1A2SLC1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | claimed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | LTA4H 4516/4885FOLH1 1381/4885HDAC3 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.